FDA launches new program to advance neuroscience medical product development
The US Food and Drug Administration (FDA) has launched the Neuroscience Advancement and Innovation Nexus (NAIN), a new program designed to strengthen the science, tools and regulatory approaches supporting medical product development for conditions affecting the brain and nervous system.
NAIN will coordinate expertise across the FDA’s drug, biologics and medical device centers. Its first initiative, the Alzheimer’s Prevention Accelerator, will explore ways to advance prevention and early-intervention drug development.
Challenges faced by neuroscience medical product developers
Neuroscience programs face persistent development challenges. Disease biology may be incompletely understood, patient populations can be highly variable, and clinically meaningful benefit may be difficult to demonstrate, particularly where disease progression takes place over many years.
At the same time, biomarkers, digital health technologies and other development tools are creating opportunities to improve patient selection, measurement and evidence generation. A coordinated, cross-center approach could help the FDA consider these tools alongside the full product landscape, including drugs, biologics and devices.
What is NAIN?
NAIN is intended to provide a coordinated FDA forum for scientific and regulatory questions that span product types. It will bring together expertise from the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health.
The program has a broad remit covering neurological and psychiatric disorders, substance use disorders and pain. The FDA also plans to engage patients, industry, academia and other stakeholders as the initiative develops.
Alzheimer’s prevention is the first priority
As its first initiative, NAIN is launching the Alzheimer’s Prevention Accelerator. The FDA says the initiative will consider innovative approaches to prevention and early-intervention trials, with particular attention to:
• selection and definition of trial populations;
• stage-appropriate clinical endpoints; and
• evidentiary approaches for demonstrating prevention or delayed cognitive decline.
Speak to a regulatory expert
Boyds’ Regulatory Affairs team supports biotechnology and pharmaceutical companies across the development lifecycle, including US regulatory strategy, IND planning, agency interactions and integrated submission support. Our multidisciplinary specialists can help teams translate evolving expectations into clear, evidence-based development plans.
To discuss the NAIN program or your neuroscience project, speak to a member of the Boyds team today.